Together with Sharon Bray – teacher and author of two books on writing and health – CKN welcomes you to our new Writing Series where Sharon helps readers tap into the healing power of writing during difficult times. As Sharon puts it, “Your stories matter. You are your stories. Our stories shape us and act as the lens through which we see the world. It’s through story that we make sense of our lives, reclaim our voices, and learn our words can touch others’ hearts.” Follow along with this bi-monthly series with Sharon and please send us your stories….they matter to us.
by Michael N. Linver, MD, FACR, FSBI,Co-Director of Mammography, X-Ray Associates of New Mexico, PC, Clinical Professor of Radiology, University of New Mexico School of Medicine Albuquerque, New Mexico
THE WAR AGAINST BREAST CANCER, OR THE WAR AGAINST SCREENING MAMMOGRAPHY: WHICH IS THE LEGITIMATE WAR?
The ongoing attacks directed against screening mammography remain a source of bitter disappointment for those of us who are focused on another war on a daily basis, that against a real killer known as breast cancer. We have a powerful weapon in the high quality mammogram used as a screening method: we know this based on real science, stemming from the randomized controlled trials (RCT’s) conducted over the past 30 years that tested the impact of early detection on the breast cancer death rate. The RCT is the most valid measure of the value of any test, and mammography screening has been measured by this method more than any other test in the history of medicine. The RCT works by evaluating an intervention (in this case, the mammogram) offered to a large group of randomly selected women (study group), and compares the outcome (in this case, death due to breast cancer) against a similar large randomized group not offered a mammogram (control group). The difference in death rates between the groups is then measured after a sufficiently long period of time, usually several years, to allow for a meaningful statistical analysis.
The largest RCT was conducted in Sweden between 1977 and 1985 [1,2], led by Drs. Laszlo Tabar and Gunnar Fagerberg, and showed a 31% decrease in deaths from breast cancer among the women offered mammograms versus those who were not. The benefit was actually much greater than 31%, as the study group included 15% of women who chose not to accept the invitation to have a screening mammogram, and the control group included some who chose to obtain a mammogram outside the RCT. When this study and other studies evaluated the impact on those women who actually attended screening regularly, the decrease in mortality was 43% . Six other RCT’s from the United States and Europe showed a similar benefit of decreased death rate in the groups offered screening mammography , all of which proved overwhelmingly supportive of all women receiving screening mammograms on a regular basis. The benefit of screening was demonstrated in every age group beginning at age 40. As a result, screening mammography began in earnest around the world.
There was a notable exception: the so-called “Canadian studies”, one for women 40-49, and the other for women 50-59, both of which showed no benefit to the women being offered mammography [5,6]. However, these studies have been criticized time and time again by the scientific community for unacceptable mammography quality and improper randomization: any woman could volunteer to be included in the studies, and every woman was given a thorough physical examination by a trained examiner before being assigned to either the control group or the study group [7,8]. In fact, these studies were thrown out as true RCT’s by the World Health Organization in 2000 .
Despite serious flaws in the Canadian studies, it is these that individuals opposed to screening mammography have continually promoted as their “proof” that screening mammography does not work [10,11,12].
The RCT data are the most powerful we have for measuring the value of a medical test, and they have proved beyond a doubt that early detection and treatment of breast cancer in an early stage results in a significantly lower death rate from the disease. Real world validation can be found in the outcomes of the organized government-run mammography screening programs throughout the world, of which there are now more than 25 . These have been operating on a large scale for many years as a result of the compelling findings of the RCT’s, and have now involved more than 20 million women. The results of virtually every one of these programs showed a 30-50% decrease in breast cancer death 14]. Again, the data are overwhelming that early detection through high quality screening mammography is making a difference, and that this benefit is appreciated in all age groups beginning at age 40 [15,16,17]. The explanation for this success: screening cuts back on the rate of advanced, less controllable cancers.
However, those opposing early detection – largely pseudo-skeptics with no experience in screening – have stubbornly refused to acknowledge the huge benefits of screening mammography as demonstrated in the RCT’s and the organized screening programs. Instead, they have focused on the so-called “harms” of mammography, most notably anxiety and overdiagnosis [10,11,12]. Although it is true that there is always some transient anxiety associated with having a mammogram, the anxiety created by a far-advanced breast cancer in a woman who had been advised not to obtain a screening mammogram would seem much greater; yet the opponents of screening focus only on the former.
The authors of the most recent attack on mammography screening  focus on overdiagnosis, claiming that there is a large number of cancers detected by mammography that would never surface as a potential killing cancer in the woman’s lifetime. This issue has already been taken seriously by the scientific community and has been addressed in numerous peer reviewed publications. All of these have shown that the demonstrated benefit of mammography in reducing the breast cancer death rate by 30-50% far outweighs the overdiagnosis (the claimed “harm”) that may exist in no more than1-5% of the cases . Strangely enough, the anti-screening campaign focusing on the harms of mammography originates in Denmark, a country with one of the highest breast cancer death rates in Europe. Fortunately, mammography screening has now started in Denmark as well, and shows a 25% decrease in breast cancer deaths. .
The United States Preventive Services Task Force (USPSTF) 2009 and 2016 recommendations [20,21] also focused on the so-called “harms” of screening mammography, especially anxiety and overdiagnosis, as being greater that the benefit, i.e. preventing death from breast cancer. With virtually no valid data to support their claims of “harms”, they in essence made a value judgment rather than a scientific judgment. They also focused on the data from the “Canadian” trials and refused to consider the powerful collected data from the multiple organized screening programs from around the globe . The real irony of the above is that in 2014, the organized service screening programs involving 3 million women throughout Canada (representing 85% of the population) published their results, and showed at least a 40% reduction in breast cancer deaths among the screened women, including those in the 40-49 age group , a far cry from the results of the older “Canadian” trials.
Apparently, such results and other similar screening data failed to impress the USPSTF: in 2016, they recommended no screening mammography for women of average risk in their 40’s or above age 74, and mammograms every two years for women 50-74. Even more perturbing, these recommendations have the power of law under the Affordable Care Act, and would have become the guidelines for both government and private institutions, had Congress not passed a two year moratorium, allowing women to continue to have mammograms covered without a deductible yearly beginning at age 40 . This moratorium is due to expire at the end of 2017, so there is still considerable concern that many women will lose affordable access to screening mammography under these terms.
Women should keep in mind that breast cancer has been an uncontrollable disease for thousands of years, since the first case has been reported; the physicians in our generation are the very first in the history of medicine who can provide a life-saving tool for women with breast cancer: early detection and treatment at an early stage of the disease. It is also important to realize that the quality of the breast cancer screening tests has improved significantly since the RCTs were carried out. We now have digital mammography, which has been shown to find more cancers than the older film screen images , and several other new methods, such as tomosynthesis, whole breast ultrasound and MRI (magnetic resonance imaging), all of which find up to 20-30% more cancers than digital mammography does alone [24, 25, 26]. The women living in this generation are the very first in history who benefit from the advent of modern technology and thorough scientific validation of these new diagnostic tools. Early detection offers many advantages to women: fewer women with breast cancer will die from this dreaded disease, less radical treatment methods can be used, which improve the life quality of the patient, and on average, the breast cancer patients live 16 years longer than those whose disease is detected late. Our task is to continue to train and update the physicians and nurses who detect, diagnose and treat breast cancer patients, and to inform women about the powerful life-saving effect of early detection .
Click here to read the Table of Contents for the series: Breast Cancer Screening, Mammography and “Alternative Facts”
1. Tabar L, Fagerberg CJ, Gad A, et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet. 1985;1(8433):829-32.
2. Tabar L, Vitak B, Chen TH, et al. Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology. 2011;260(3):658-63.
3. Swedish Organized Service Screening Evaluation Group. Reduction in Breast Cancer Mortality from Organized Service Screening with Mammography: 1. Further Confirmation with Extended Data. Cancer Epidemiol Biomarkers Prev. 2006;15(I1):45-51.
4. Smith RA, Duffy SW, Gabe R et al. The Randomized Trials of Breast Cancer Screening: What have we learned? Radiol Clin N Am. 2004;42:793-806.
5. Miller AB, Baines CJ, To T, et al. Canadian National Breast Screening Study: 1. Breast Cancer Detection and Death Rates among Women aged 40 to 49 Years. Can Med Assoc J. 1992;147:1459-76.
6. Miller AB, Baines CJ, To T, et al. Canadian National Breast Screening Study: 1. Breast Cancer Detection and Death Rates among Women aged 50 to 59 Years. Can Med Assoc J. 1992;147:1477-88.
7. Kopans DB, Feig SA. The Canadian National Breast Screening Study: a Critical Review. Am J Roentgenol. 1993;161:755-60.
8. Boyd NF. The Review of the Randomization in the Canadian National Breast Screening Study. Is the Debate Over? Can Med Assoc J. 1997;156:207-9.
9. IARC Handbook of Cancer Prevention. Vol 7, pp 100-102.
10. Gotzsche PC, Olsen O. Is Screening for Breast Cancer with Mammography Justifiable? Lancet. 2000;355(9198):129-134.
11. Welch HG, Proroc PC, O’Malley HJ et al. Breast Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness. NEJM. 2016;375:1438-47.
12. Jorgensen KJ, Gotzsche PC, Kalager M et al. Breast Cancer Screening in Denmark: A Cohort Study of Tumor Size and Overdiagnosis. Ann Intern Med. January 10 2017; DOI:10.7326/P16-9129.
13. Breast Cancer Screening Programs in 26 ICSN Countries, 2012: Organization, Policies, and Program Reach. U.S. National Institutes of Health International Cancer Screening Network website. http://appliedresearch.cancer.gov/iscn/breast/screening.html.
14. Fitzgerald SP. Breast-Cancer Screening–Viewpoint of the IARC Working Group.
N Engl J Med. 2015 Oct 8;373(15):1479. doi: 10.1056/NEJMc1508733#SA3.
15. Nickson C, Mason KE, English DR et al. Mammographic Screening and Breast Cancer Mortality: a Case-control Study and Meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012 Sep:21(0):1479-88.
16. Coldman A, Phillips N, Wilson C et al. Pan-Canadian Study of Mammography Screening and Mortality from Breast Cancer. J Natl Cancer Inst. 2014 Oct 1:106(11)
17. Gabe R, Duffy SW. Evaluation of Service Screening Mammography in Practice: the Impact on Breast Cancer Mortality. Ann Oncol. 2005;16 Suppl 2:153-62.
18. Duffy, SW, Olorunsola Agbaje, Tabar L, et al.: Overdiagnosis and overtreatment from two trials of mammographic screening for breast cancer. Br Ca Research Dec 2005 Vol 7, No 6 pp 258-265.
19. Christiansen P, Vejborg I, Kroman N, et al. Position paper: breast cancer screening, diagnosis, and treatment in Denmark. Acta Oncol. 2014 Apr;53(4):433-44.
doi: 10.3109/0284186X.2013.874573. Epub 2014
20. U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151:716-26.
21. Siu AL; U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2016;164:279-96.
23. Pisano ED, Gatsonis C, Hendrick E et al. Diagnostic Performance of Digital versus Film Mammography for Breast-Cancer Screening. J Engl J Med 2005;353:1773-1783.
24. Friedewald SM, Rafferty EA, Rose SL et al. Breast Cancer Screening Using Tomosynthesis in Combination with Digital Mammography. JAMA. 2014:311(24):2499-2507.
25. Berg WA, Blume JD, Cormack JB. Combined Screening with Ultrasound and Mammography versus Mammography Alone in Women with Elevated Risk of Breast Cancer. JAMA. 2008;299(18):2151-2163.
26. Berg WA, Zhang Z, Lehrer D et al. Detection of Breast Cancer with Addition of Annual Screening Ultrasound or a Single Screening MRI to Mammography in Women with Elevated Breast Cancer Risk. JAMA. 2012;307(13):1394-404.
27. Tabar L, Chen THH, Yen AMF et al. Detection, Diagnosis and Treatment of Early Breast Cancer Requires Creative Intedisciplinary Teamwork. Semin Breast Dis 2005.8:4-9.
The opinions expressed in this article are the author’s own and do not reflect the view of Cancer Knowledge Network or Multimed Inc.
Dr. Linver is Director of Mammography for X-Ray Associates of New Mexico, P.C., in Albuquerque, and Clinical Professor of Radiology at the University of New Mexico. He is a graduate of the University of Michigan, and the University of Pittsburgh School of Medicine. He completed his post-graduate medical training at the University of California at San Francisco, Vanderbilt University, and the University of New Mexico. He has been a specialist in Breast Imaging for the past 30 years.
Dr. Linver is a busy lecturer on mammography, having presented over 1,100 lectures in 37 states in the U.S. & in 24 other countries around the world. He is the author of over 60 published articles and chapters of textbooks on mammography, and is a strong political proponent of quality mammography. Toward this end, he spearheaded the successful campaign to enact mandated quality mammography screening legislation in New Mexico in 1990, and served on the original National Mammography Quality Assurance Advisory Committee to the FDA under MQSA from 1994 to 1997. He helped author the A.H.C.P.R. document, “Quality Determinants of Mammography”, and co-chaired the American Cancer Society’s consensus conference in Chicago on screening mammography guidelines for pre-menopausal women in 1997.
He is past president of the New Mexico chapters of both the American College of Radiology (ACR) and the American Cancer Society. He was a member of the Board of Directors of the National Consortium of Breast Centers, and is a long-standing member of the ACR BI-RADS Committee. He currently serves as the Chair of the Subcommittee on BI-RADS Ultrasound for the ACR. He is a Fellow of the American College of Radiology, and was recently elected a Fellow of the Society of Breast Imaging, the first ever to receive this honor in the entire Mountain West. He is the recipient of the Nancy Floyd Haworth Memorial Lectureship “Spirit of Hope” award, the “People’s Caring” award from People Living Through Cancer, the “Unsung Hero” award from the NCSL Women’s Network, and the “Lifesaver” award from the American Cancer Society. He has been voted the best doctor in Radiology by the physicians of Albuquerque in Albuquerque Magazine’s “Top Doc” poll every year from 2005 to 2017. In 2010, he was chosen as one of the 10 most effective Radiology Educators in the United States by the subscribers and members of AuntMinnie.com.
“Some types of screening are a good idea — colorectal, for example,” said the lead author, Dr. Karsten Juhl Jorgensen, deputy director of the Nordic Cochrane Center. “But breast cancer has a biology that doesn’t lend itself to screening. Healthy women get a breast cancer diagnosis, and this has serious psychological consequences and well-known physical harms from unnecessary treatment. We’re really doing more harm than good.” The New York Times The Downside of Breast Cancer Screening
After reading the above NYT article, we wanted to explore both sides of the Breast Cancer Screening debate so we invited professionals and patients to weigh in with their opinions. We believe patients should be informed before making health care decisions and that includes reading evidence-based research reports as well as hearing personal narratives from patients who have gone through similar experiences.
Our intention with this series is to inform our readers about the facts surrounding breast cancer screening and the implications toward informed decision making.
“ALTERNATIVE FACTS” AND BREAST CANCER SCREENING
“Alternative Facts” (AF) recently appeared as an outrageous concept in the “political arena”. What most do not realize is that “alternative” facts have been promulgated for decades by those seeking to reduce access to breast cancer screening. This has led to the pseudo “debate” about screening that has persisted for decades due to the “alternative facts” that have been manufactured to keep the “debate” going. Each time an “alternative fact” has been generated to cast doubt on screening, it has been refuted by science ([i]). Unfortunately, as each (true) fact has been established, new “alternative facts” have been manufactured. The article in the Annals of Internal Medicine cited by Nicholas Bakalar in the New York Times is an example of misinformation that got past poor peer review at a major journal and was published despite its lack of scientific rigor. The study from Norway ([ii]), cited by Mr. Bakalar ([iii]), claiming massive “overdiagnosis” due to mammography had no data on who actually had mammograms and no data on which cancers were detected by mammography. How can a test (mammography) be faulted when the “investigators” had no information on who actually had the test? In an earlier, scientifically more rigorous study from Denmark, Njor, et al looked at actual individual patient data and they found that there was little if any “overdiagnosis” due to screening ([iv]) and, another study found, contrary to the conclusions of the paper reviewed by Bakalar, that screening had in fact resulted in a marked decline in deaths from breast cancer in Denmark ([v]).
by Constantine Kaniklidis *, Research Director, No Surrender Breast Cancer Foundation (NSBCF) **
Understanding – and Measuring – Overdiagnosis Overdiagnosis occurs when the patient, were it not for screening, would have died of some other non-cancer cause without ever having been diagnosed with malignancy. Overdiagnosis estimates are fraught with many complex limitations and challenges, but overdiagnosis estimates can be “normalized” by drawing on only studies restricted to actual screening-attendant women (as opposed to only screening-invited women) and which also control for the major known confounding factors. The EUROSCREEN review (2 million women age 50 or older in 18 countries) which met these requirements found overdiagnosis as being just 6.5%, and autopsy studies find only a small degree of overdiagnosis (under 10% total, just 1.3% for invasive breast cancers only).
Karsten Juhl Jørgensen, MD, DrMedSci, Deputy Director, The Nordic Cochrane Centre, Rigshospitalet, Copenhagen, Denmark.
Breast cancer screening has been disputed for many years. The origin of the dispute is the conflicting results reached by the nine original randomised breast screening trials. One of these trials estimated a 42% reduction in breast cancer mortality while others estimated no reduction, or only a smaller benefit . The most important harm is also disputed. As for prostate cancer screening, there is now general agreement that breast screening leads to the detection of some tumors that would not have been detected or caused health problems in the absence of screening [2,3,4]. The dispute relates to how many such overdiagnosed tumors there are.